Currently, anti-inflammatory drugs used to treat IBD are unable to attenuate intestinal fibrosis; thus, their combined action with PPARγ agonists may be a promising therapeutic approach to treat IBD. This evidence concerns the gene PPARG and inflammatory bowel disease.